Successful Treatment of Drooling in Children with Neurological Disorders with Botulinum Toxin A or B

Abstract

Drooling is a common and severe problem in children with neurological disorders and is caused by a disturbed coordination of orofacial and palatolingual muscles. Botulinum toxin could be a successful option to reduce excessive sialorrhea in children with neurological disorders. In 30 children with cerebral palsy or neurodegenerative disorder we injected under ultrasound guidance either botulinum toxin A or botulinum toxin B into the parotid and submandibular glands on both sides. All injections were well tolerated without general anaesthesia. Drooling severity at baseline and reduction of sialorrhea during treatment was measured using a parent's questionnaire and rated using the Teachers Drooling Scale (TDS). Reduction of sialorrhea was achieved two weeks after injection, with a positive effect lasting about three to four months in most children. 83% showed a good response to botulinum toxin after first injection, but only in 50% treatment was continued. We found no significant differences between botulinum toxin A or B. Side effects were observed in 5 children with viscous saliva and in one child a unilateral parotitis was observed. Treatment of drooling with botulinum toxin into the salivary glands is a safe and easy therapeutic option for children with neurological disorders to improve life quality.

botulinum toxin A - botulinum toxin B - drooling - sialorrhea - salivary glands

References

• 1 Blasco PA, Stansbury JC. Glycopyrrolate treatment of chronic drooling.  ArchPediatr Adolesc Med. 1996;  150 932-935
• 2 Banerjee KJ, Glasson C, O’Flaherty SJ. Parotid and submandibular botulinumtoxin A injections for sialorrhoea in children with cerebral palsy.  Dev Med Child Neurol. 2006;  48 883-887
• 3 Berweck S, Schroeder S, Lee SH. et al . Secondary non-response due to anitbody formation in a child after three injections od botulinum toxin B into the salivary glands.  Dev Med Child Neurol. 2007;  49 62-64
• 4 Camp-Bruno JA, Winsberg BG, Green-Parsons AR. et al . Efficacy of benzotropine therapy for drooling.  Dev Med Child Neurol. 1989;  31 309-319
• 5 Crysdale WS, Raveh E, MacCann C. et al . Management of drooling in individuals with neurodisability: a surgical experience.  Dev Med Child Neurol. 2001;  43 379-383
• 6 Dressler D, Eleopra R. Clinical use of non-A botulinum toxins: botulinum toxin type B.  Neurotox Res. 2006;  9 121-125
• 7 Ellies M, Rohrbach-Volland S, Arglebe C. et al . Successful management of drooling with botulinum toxin A in neurologically disabled children.  Neuropediatrics. 2002;  33 327-330
• 8 Ellies M, Laskawi R, Rohrbach-Volland S. et al . Up-to-date report of botulinum toxin therapy in patients with drooling caused by different etiologies.  J Oral Maxillofac Surg. 2003;  61 454-457
• 9 Firth AY, Walker K. Visual side-effects from transdermal scopolamine (hyoscine).  Dev Med Child Neurol. 2006;  48 137-138
• 10 Frederick FJ, Stewart IF. Effectiveness of transtympanic neurectomy in management of sialorrhea occurring in mentally retarded patients.  J Otolaryngol. 1982;  11 289-292
• 11 Harris SR, Purdy AH. Drooling and its management in cerebral palsy.  Dev Med Child Neurol. 1987;  29 807-811
• 12 Hassin-Baer S, Scheuer E, Buchman AS. et al . Botulinum toxin injections for children with excessive drooling.  J Child Neurol. 2005;  20 120-123
• 13 Heine RG, Catto-Smith AG, Reddihough DS. Effect of antireflux medication on salivary drooling in children with cerebral palsy.  Dev Med Child Neurol. 1996;  38 1030-1036
• 14 Hockstein NG, Samadi DS, Gendron K. et al . Sialorrhea: A management challenge.  Am Fam Physician. 2004;  69 2628-2634
• 15 Jongerius PH, Rotteveel JJ, Hoogen F van den. et al . Botulinum toxin A: a new option for treatment of drooling in children with cerebral palsy. Presentation of a case series.  Eur J Pediatr. 2001;  160 509-512
• 16 Jongerius PH, Hoogen FJA van den, Limbeek J van. et al . Effect of botulinum toxin in the treatment of drooling: a controlled clinical trial.  Pediatrics. 2004;  114 620-627
• 17 Lewis DW, Fontana C, Mehallick LK. et al . Transdermal scopolamine for reduction of drooling in developmentally delayed children.  Dev Med Child Neurol. 1994;  36 484-486
• 18 Mankarious LA, Bottrill IA, Huchzermyer PM. et al . Long-term follow-up of submandibular duct rerouting for the treatment of sialorrhea in the pediatric population.  Otolaryngol Head Neck Surg. 1999;  120 303-307
• 19 Mier RJ, Bachrach SJ, Lakin RC. et al . Treatment of sialorrhea with glycopyrolate: a double-blind, dosage-ranging study.  Arch Pediatr Adolesc Med. 2000;  154 1214-1218
• 20 Pal PK, Calne DB, Calne S. et al . Botulinum toxin A as a treatment for drooling saliva in PD.  Neurology. 2000;  54 244-247
• 21 Panarese A, Ghosh S, Hodgson D. et al . Outcome of submandibular duct re-implantation for sialorrhea.  Clin Otolaryngol. 2001;  26 143-146
• 22 Porta M, Gamba M, Bertacchi G. et al . Treatment of sialorrhea with ultrasound guided botulinum toxin type A injection in patients with neurological disorders.  J Neurol Neurosurg Psychiatr. 2001;  70 538-540
• 23 Reid SM, Johnstone BR, Westbury C. et al . Randomized trial of botulinum toxin injections into the salivary glands to reduce drooling in children with neurological disorders.  Dev Med Child Neurol. 2008;  50 123-128
• 24 Schroeder S, Kling T, Huß K. et al . Long-term treatment of drooling in children with neurological disorders using botulinum toxin.  Neuropediatrics. 2008;  39 92-100A
• 25 Suskind DL, Tilton A. Clinical study of botulinum-A toxin in the treatment of sialorrhea in children with cerebral palsy.  Laryngoscope. 2002;  112 73-81
• 26 Burg JJ Van der, Jongerius PH, Hulst K van. et al . Drooling in children with cerebral palsy: effect of salivary flow reduction on daily life and care.  Dev Med Child Neurol. 2006;  48 103-107
• 27 Burg JJ Van der, Jongerius PH, Limbeek J. et al . Social interaction and self-esteem of children with cerebral palsy after treatment for severe drooling.  Eur J Pediatr. 2006;  165 37-41

Correspondence